Kuang, Yanan
Siddiqui, Bilal
Hu, Jiani
Pun, Matthew
Cornwell, MacIntosh http://orcid.org/0000-0002-3041-4410
Buchwalter, Gilles
Hughes, Melissa E.
Wagle, Nikhil
Kirschmeier, Paul
Jänne, Pasi A.
Paweletz, Cloud P.
Lin, Nancy U.
Krop, Ian E.
Barry, William T.
Winer, Eric P.
Brown, Myles
Jeselsohn, Rinath
Article History
Received: 16 March 2018
Revised: 10 July 2018
Accepted: 13 July 2018
First Online: 2 August 2018
Competing interests
: Dr. Pasi A. Jänne has received consulting fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmaceuticals, Roche/Genentech, Chugai Pharmaceuticals, ACEA Biosciences, Ignyta, LOXO Oncology, Ariad Pharmaceuticals, Eli Lilly and Company and Araxes Pharmaceuticals; sponsored research funding from Astellas Pharmaceuticals, AstraZeneca, Daiichi Sankyo, PUMA and Eli Lilly and Company and receives post-marketing royalties on DFCI owned intellectual property on EGFR mutations licensed to Lab Corp. Dr. Cloud P. Paweletz has received honoraria from AstraZeneca, Clovis Oncology, and Bio-RAD and is a SAB member of DropWorks. Drs. Cloud P. Paweletz, Yanan Kuang, and Pasi A. Jänne are inventors on a pending patent related to non-invasive genotyping of cfDNA. The other authors declare no competing interests.